Ever Supreme Bio Technology Co., Ltd.(TW:6712)
NT$148.00-0.50 (-0.34%)
TW:6712
Ever Supreme Bio Technology Co., Ltd. financials statements
NT$148.00
At close:-0.50 (-0.34%)
Ever Supreme Bio Technology Co., Ltd. (6712) Ratios
Ever Supreme Bio Technology Co., Ltd. Ratios
TW:6712's free cash flow for Q2 2026 was NT$140.72M. For the 2026 fiscal year, TW:6712's free cash flow was decreased by NT$-39.00K and operating cash flow was NT$140.76M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.78 | 3.72 | 6.57 | 8.89 | 15.20 |
| Quick Ratio | 1.60 | 3.47 | 6.27 | 8.35 | 14.61 |
| Cash Ratio | 0.53 | 0.92 | 1.45 | 2.16 | 6.64 |
| Solvency Ratio | 0.95 | 1.16 | 2.45 | 1.30 | 3.25 |
| Operating Cash Flow Ratio | 1.27 | 1.34 | 1.82 | 1.95 | 1.41 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | -11.11 |
| Net Current Asset Value | NT$ 274.88M | NT$ 881.43M | NT$ 1.29B | NT$ 1.27B | NT$ 1.34B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.02 | 0.00 | 0.00 | 0.01 | 0.02 |
| Debt-to-Equity Ratio | 0.03 | 0.00 | 0.00 | 0.01 | 0.02 |
| Debt-to-Capital Ratio | 0.02 | 0.00 | 0.00 | 0.01 | 0.02 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.31 | 1.19 | 1.13 | 1.10 | 1.07 |
| Debt Service Coverage Ratio | 400.51 | 3186.13 | 2845.30 | 464.26 | -35.01 |
| Interest Coverage Ratio | 478.73 | 3369.54 | 1680.26 | 518.85 | 643.11 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | -0.00 |
| Interest Debt Per Share | 0.45 | 0.04 | 0.07 | 0.25 | 0.47 |
| Net Debt to EBITDA | -0.40 | -0.61 | -0.50 | -1.12 | -1.40 |
| Profitability Margins | |||||
| Gross Profit Margin | 70.89% | 70.68% | 63.92% | 66.06% | 55.94% |
| EBIT Margin | 43.14% | 49.35% | 82.18% | 42.17% | 90.57% |
| EBITDA Margin | 45.42% | 52.66% | 86.44% | 47.83% | 98.73% |
| Operating Profit Margin | 43.14% | 45.10% | 44.53% | 42.17% | 90.57% |
| Pretax Profit Margin | 51.53% | 49.34% | 82.15% | 42.09% | 90.42% |
| Net Profit Margin | 42.20% | 39.33% | 71.12% | 31.99% | 84.22% |
| Continuous Operations Profit Margin | 42.20% | 39.33% | 71.12% | 31.99% | 84.22% |
| Net Income Per EBT | 81.90% | 79.71% | 86.58% | 76.00% | 93.14% |
| EBT Per EBIT | 119.44% | 109.39% | 184.47% | 99.81% | 99.84% |
| Return on Assets (ROA) | 21.42% | 17.19% | 25.98% | 10.17% | 18.27% |
| Return on Equity (ROE) | 28.13% | 20.47% | 29.27% | 11.20% | 19.48% |
| Return on Capital Employed (ROCE) | 27.75% | 23.31% | 18.31% | 14.62% | 20.63% |
| Return on Invested Capital (ROIC) | 22.58% | 18.56% | 15.81% | 11.08% | 19.22% |
| Return on Tangible Assets | 21.57% | 17.27% | 26.12% | 10.23% | 18.37% |
| Earnings Yield | 3.12% | 3.00% | 4.28% | 1.70% | 3.62% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.29 | 4.63 | 7.50 | 7.31 | 13.04 |
| Payables Turnover | 6.82 | 10.89 | 11.73 | 7.32 | 12.90 |
| Inventory Turnover | 3.91 | 3.42 | 3.96 | 2.41 | 3.41 |
| Fixed Asset Turnover | 13.63 | 19.22 | 11.70 | 6.99 | 3.51 |
| Asset Turnover | 0.51 | 0.44 | 0.37 | 0.32 | 0.22 |
| Working Capital Turnover Ratio | 1.66 | 0.86 | 0.59 | 0.47 | 0.49 |
| Cash Conversion Cycle | 124.89 | 151.98 | 109.68 | 151.43 | 106.86 |
| Days of Sales Outstanding | 85.09 | 78.78 | 48.65 | 49.92 | 28.00 |
| Days of Inventory Outstanding | 93.30 | 106.71 | 92.15 | 151.35 | 107.17 |
| Days of Payables Outstanding | 53.50 | 33.51 | 31.12 | 49.84 | 28.31 |
| Operating Cycle | 178.38 | 185.49 | 140.81 | 201.27 | 135.17 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 6.09 | 5.46 | 5.15 | 4.26 | 1.82 |
| Free Cash Flow Per Share | 6.03 | 5.39 | 5.08 | 4.19 | 1.76 |
| Dividend Paid and CapEx Coverage Ratio | 1.30 | 0.99 | 2.97 | 1.01 | 29.17 |
| Capital Expenditure Coverage Ratio | 93.72 | 79.25 | 72.33 | 57.05 | 29.17 |
| Operating Cash Flow Coverage Ratio | 13.84 | 154.83 | 71.51 | 17.87 | 3.94 |
| Operating Cash Flow to Sales Ratio | 0.53 | 0.47 | 0.56 | 0.51 | 0.31 |
| Free Cash Flow Yield | 3.86% | 3.55% | 3.30% | 2.65% | 1.28% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 32.01 | 36.70 | 23.39 | 58.89 | 27.61 |
| Price-to-Sales (P/S) Ratio | 13.51 | 13.13 | 16.62 | 18.84 | 23.28 |
| Price-to-Book (P/B) Ratio | 9.00 | 6.83 | 6.84 | 6.60 | 5.38 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 25.90 | 28.19 | 30.31 | 37.70 | 77.95 |
| Price-to-Operating Cash Flow Ratio | 25.63 | 27.84 | 29.89 | 37.04 | 75.28 |
| Price-to-Earnings Growth (PEG) Ratio | 1.79 | -0.99 | 0.16 | -1.28 | -0.07 |
| Enterprise Value Multiple | 29.34 | 24.32 | 18.73 | 38.27 | 22.18 |
| Enterprise Value | 13.56B | 11.96B | 12.27B | 11.49B | 9.61B |
| EV to EBITDA | 29.34 | 24.32 | 18.73 | 38.27 | 22.18 |
| EV to Sales | 13.33 | 12.81 | 16.19 | 18.31 | 21.89 |
| EV to Free Cash Flow | 25.56 | 27.51 | 29.51 | 36.63 | 73.32 |
| EV to Operating Cash Flow | 25.28 | 27.16 | 29.11 | 35.99 | 70.81 |
| Tangible Book Value Per Share | 17.20 | 22.12 | 22.37 | 23.77 | 25.30 |
| Shareholders’ Equity Per Share | 17.35 | 22.24 | 22.50 | 23.93 | 25.45 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.18 | 0.20 | 0.13 | 0.24 | 0.07 |
| Revenue Per Share | 11.56 | 11.58 | 9.26 | 8.38 | 5.88 |
| Net Income Per Share | 4.88 | 4.55 | 6.58 | 2.68 | 4.96 |
| Tax Burden | 0.82 | 0.80 | 0.87 | 0.76 | 0.93 |
| Interest Burden | 1.19 | 1.00 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.23 | 0.16 | 0.13 | 0.14 | 0.19 |
| SG&A to Revenue | 0.03 | 0.05 | 0.06 | 0.06 | 0.10 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.25 | 0.96 | 0.78 | 1.21 | 0.34 |
Currency in TWD
